Duloxetine 30–60mg
Brand names: Cymbalta, Yentreve
Duloxetine is a serotonin-noradrenaline reuptake inhibitor (SNRI) used in the orthopaedic setting for chronic musculoskeletal pain and diabetic peripheral neuropathic pain, and at the higher of these doses also for depression and generalised anxiety.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It potentiates descending inhibitory pain pathways and central monoaminergic neurotransmission by inhibiting reuptake of serotonin and noradrenaline.
Prescribing in practice
- Do not stop abruptly — taper to avoid a discontinuation syndrome of dizziness, paraesthesia, anxiety and sleep disturbance.
- Avoid combining with MAOIs and use caution with other serotonergic drugs (triptans, tramadol, SSRIs) because of serotonin syndrome risk.
- Contraindicated in uncontrolled hypertension and significant hepatic impairment; can raise blood pressure and is not recommended in severe renal impairment.
Monitoring
Monitor blood pressure, mood and for emergent suicidal ideation early in treatment or after dose changes.
Counselling the patient
- Pain benefit may take a couple of weeks to build up.
- Do not stop suddenly; speak to your prescriber about reducing gradually.
- Report worsening mood, agitation or thoughts of self-harm.
Evidence & guidelines
NICE recommends duloxetine as a first-line option for neuropathic pain and for chronic primary pain in adults.
Reference: NICE NG226 (Osteoarthritis 2022); NICE NG59 (Low Back Pain 2016); NICE NG193 (Neuropathic Pain); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Hip Fracture Management · NICE CG124 / BOA 2020
- Distal Radius Fracture · BOA / NICE
- Ankle Fracture Management · BOA / Lauge-Hansen classification
- Metastatic Spinal Cord Compression · NICE CG75 2020
- Open Fracture Management · BOA/BAPRAS 2017
- OrthoPath: Upper Limb ED Triage · OrthoPath ED Tool — ReviseMRCEM.com